Anmelden Kostenlos registrieren

Knight Therapeutics Einnahmen

Was ist das Einnahmen von Knight Therapeutics?

Einnahmen von Knight Therapeutics, Inc. ist 3.50%

Was ist die Definition von Einnahmen?

Das jährliche Umsatzwachstum der letzten 3 Jahre ist das durchschnittliche Umsatzwachstum der letzten 3 Jahre von einem Jahr zum nächsten.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Einnahmen von Unternehmen in Health Care Sektor auf TSX im Vergleich zu Knight Therapeutics

Was macht Knight Therapeutics?

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Unternehmen mit einnahmen ähnlich Knight Therapeutics